References
- D’Cruz D, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587–596.
- Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13–BLK and ITGAM–ITGAX. N Engl J Med. 2008;358(9):900–909.
- Möller B, Pruijm M, Adler S, et al. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis. 2015;74(4):718–723.
- Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016–1027.
- Shin W, Lee HT, Lim H, et al. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun. 2018;9(1):1200.
- Wu H, Deng Y, Feng Y, et al. Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity. Cell Mol Immunol. 2018;15(7):676–684.
- Lund FE. Cytokine-producing B lymphocytes—key regulators of immunity. Curr Opin Immunol. 2008;20(3):332–338.
- Ngo VN, Cornall RJ, Cyster JG. Splenic T zone development is B cell dependent. J Exp Med. 2001;194(11):1649–1660.
- Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260–263.
- Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune–based rheumatic diseases. Arthritis Rheum. 2001;44(6):1313–1319.
- Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.
- Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475–3486.
- Mercado U. [B lymphocyte stimulator in systemic lupus erythematosus]. Rev Med Inst Mex Seguro Soc. 2012;50(4):349–350.
- Bhattacharya J, Pappas K, Toz B, et al. Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Mol Med. 2018;24(1):24.
- Mandik-Nayak L, Ridge N, Fields M, et al. Role of B cells in systemic lupus erythematosus and rheumatoid arthritis. Curr Opin Immunol. 2008;20(6):639–645.
- Vincent FB, Kandane-Rathnayake R, Koelmeyer R, et al. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunol. 2019;8(4):e01047.
- Salazar-Camarena DC, Ortiz-Lazareno P, Marin-Rosales M, et al. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine. 2019;114:115–127.
- Suso JP, Posso-Osorio I, Jimenez CA, et al. Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes. Lupus. 2018;27(5):708–715.
- Schwarting A, Relle M, Meineck M, et al. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus. 2018;27(2):243–256.
- Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725–1725.
- Bossen C, Schneider P, editors. BAFF, APRIL and their receptors: structure, function and signaling. Seminars in immunology. Elsevier; 2006.
- Hamzaoui K, Houman H, Ben Dhifallah I, et al. Serum BAFF levels and skin mRNA expression in patients with Behçet’s disease. Clin Exp Rheumatol. 2008;26(4 Suppl 50):S64–S71.
- Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293(5537):2111–2114.
- Rahman ZS, Rao SP, Kalled SL, et al. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling–deficient mice. J Exp Med. 2003;198(8):1157–1169.
- Yoshimoto K, Takahashi Y, Ogasawara M, et al. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int Immunol. 2006;18(7):1189–1196.
- Schuh E, Musumeci A, Thaler FS, et al. Human plasmacytoid dendritic cells display and shed B cell maturation antigen upon TLR engagement. J Immunol. 2017;198(8):3081–3088.
- Chen M, Lin X, Liu Y, et al. The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev. 2014;25(3):301–305.
- Huang X, Wu H, Qiu H, et al. The expression of Bcl-6 in circulating follicular helper-like T cells positively correlates with the disease activity in systemic lupus erythematosus. Clin Immunol. 2016;173:161–170.
- Carrillo-Ballesteros FJ, Oregon-Romero E, Franco-Topete RA, et al. B-cell activating factor receptor expression is associated with germinal center B-cell maintenance. Exp Ther Med. 2019;17(3):2053–2060.
- Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, et al. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA. 2008;105(39):14993–14998.
- Alexaki VI, Pelekanou V, Notas G, et al. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies. Endocrinology. 2012;153(2):739–749.